Jiangsu Lianhuan Pharmaceutical Co., Ltd. (SHA:600513)
China · Delayed Price · Currency is CNY 16.76
+1.52 (9.97%)
Jul 30, 2026, 10:54 AM CST
SHA:600513 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 4,350 | 5,227 | 2,829 | 3,180 | 2,696 | 2,782 | |
Market Cap Growth | -15.10% | 84.76% | -11.04% | 17.94% | -3.08% | -6.30% |
Enterprise Value | 6,103 | 6,835 | 3,616 | 3,816 | 3,234 | 3,159 |
Last Close Price | 15.24 | 18.22 | 9.77 | 10.80 | 8.97 | 9.11 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | - | - | 33.61 | 23.55 | 19.07 | 23.41 |
PS Ratio | 1.50 | 1.93 | 1.31 | 1.46 | 1.38 | 1.69 |
PB Ratio | 2.58 | 3.11 | 1.79 | 2.10 | 1.91 | 2.17 |
P/TBV Ratio | 4.44 | 5.34 | 2.22 | 2.58 | 2.33 | 2.62 |
P/OCF Ratio | - | - | 262.77 | 19.79 | 21.13 | 20.11 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 2.11 | 2.52 | 1.67 | 1.76 | 1.65 | 1.92 |
EV/EBITDA Ratio | 63.85 | 59.13 | 19.59 | 16.19 | 13.27 | 15.83 |
EV/EBIT Ratio | - | 359.47 | 28.97 | 21.21 | 15.94 | 18.42 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.95 | 0.92 | 0.56 | 0.47 | 0.49 | 0.44 |
Debt / EBITDA Ratio | 16.84 | 13.24 | 4.76 | 2.99 | 2.83 | 2.80 |
Net Debt / Equity Ratio | 0.80 | 0.72 | 0.42 | 0.28 | 0.25 | 0.18 |
Net Debt / EBITDA Ratio | 14.27 | 10.39 | 3.55 | 1.80 | 1.47 | 1.14 |
Net Debt / FCF Ratio | -4.63 | -4.20 | -3.77 | -10.62 | -3.86 | -6.75 |
Asset Turnover | 0.74 | 0.76 | 0.74 | 0.78 | 0.77 | 0.75 |
Inventory Turnover | 3.37 | 3.24 | 2.91 | 3.80 | 3.79 | 3.77 |
Quick Ratio | 0.52 | 0.57 | 0.67 | 0.72 | 0.74 | 0.85 |
Current Ratio | 0.94 | 0.98 | 1.10 | 1.09 | 1.10 | 1.18 |
Return on Equity (ROE) | -6.00% | -5.17% | 6.88% | 10.33% | 12.35% | 11.36% |
Return on Assets (ROA) | -0.19% | 0.33% | 2.66% | 4.04% | 5.00% | 4.87% |
Return on Invested Capital (ROIC) | -0.39% | 0.74% | 4.88% | 8.38% | 10.88% | 10.62% |
Return on Capital Employed (ROCE) | -0.60% | 0.90% | 7.40% | 11.20% | 13.80% | 12.80% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jul '26 Jul 29, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | -2.64% | -1.88% | 2.97% | 4.25% | 5.24% | 4.27% |
FCF Yield | -6.67% | -5.47% | -6.15% | -1.26% | -3.45% | -1.21% |
Dividend Yield | 0.44% | 0.38% | 0.91% | 1.39% | 1.67% | 1.37% |
Payout Ratio | - | - | 60.08% | 37.94% | 38.48% | 33.48% |
Buyback Yield / Dilution | -3.18% | 0.34% | -1.03% | 0.44% | 0.46% | -1.31% |
Total Shareholder Return | -2.73% | 0.73% | -0.12% | 1.82% | 2.14% | 0.07% |